These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 32528882)

  • 1. Anti-PD-1 Therapy Response Predicted by the Combination of Exosomal PD-L1 and CD28.
    Zhang C; Fan Y; Che X; Zhang M; Li Z; Li C; Wang S; Wen T; Hou K; Shao X; Liu Y; Qu X
    Front Oncol; 2020; 10():760. PubMed ID: 32528882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients.
    Akbar S; Raza A; Mohsin R; Kanbour A; Qadri S; Parray A; Zar Gul AR; Philip A; Vijayakumar S; Merhi M; Hydrose S; Inchakalody VP; Al-Abdulla R; Abualainin W; Sirriya SA; Al-Bozom I; Uddin S; Khan OM; Mohamed Ibrahim MI; Al Homsi U; Dermime S
    Front Immunol; 2022; 13():1097117. PubMed ID: 36741391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exosomal PD-L1 and N-cadherin predict pulmonary metastasis progression for osteosarcoma patients.
    Wang J; Zhang H; Sun X; Wang X; Ren T; Huang Y; Zhang R; Zheng B; Guo W
    J Nanobiotechnology; 2020 Oct; 18(1):151. PubMed ID: 33092576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-derived exosomal PD-L1 in progression of cancer and immunotherapy.
    Rasihashemi SZ; Rezazadeh Gavgani E; Majidazar R; Seraji P; Oladghaffari M; Kazemi T; Lotfinejad P
    J Cell Physiol; 2022 Mar; 237(3):1648-1660. PubMed ID: 34825383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exosomal PD-L1 Retains Immunosuppressive Activity and is Associated with Gastric Cancer Prognosis.
    Fan Y; Che X; Qu J; Hou K; Wen T; Li Z; Li C; Wang S; Xu L; Liu Y; Qu X
    Ann Surg Oncol; 2019 Oct; 26(11):3745-3755. PubMed ID: 31087180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-FU-Induced Upregulation of Exosomal PD-L1 Causes Immunosuppression in Advanced Gastric Cancer Patients.
    Zhang M; Fan Y; Che X; Hou K; Zhang C; Li C; Wen T; Wang S; Cheng Y; Liu Y; Qu X
    Front Oncol; 2020; 10():492. PubMed ID: 32391259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients.
    Cordonnier M; Nardin C; Chanteloup G; Derangere V; Algros MP; Arnould L; Garrido C; Aubin F; Gobbo J
    J Extracell Vesicles; 2020; 9(1):1710899. PubMed ID: 32002173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating Plasma Exosomal PD-L1 Predicts Prognosis of Head and Neck Squamous Cell Carcinoma After Radiation Therapy.
    Tamari K; Minami K; Tatekawa S; Seo Y; Fukusumi T; Tanaka H; Suzuki M; Eguchi H; Takenaka Y; Hirata T; Hayashi K; Isohashi F; Shimizu S; Koizumi M; Inohara H; Ogawa K
    Adv Radiat Oncol; 2024 Feb; 9(2):101353. PubMed ID: 38405303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Jianpi Yangzheng Xiaozheng decoction alleviates gastric cancer progression via suppressing exosomal PD-L1.
    Chen Y; Liu J; Chen Y; Zhang R; Tao J; Chen X; Wang H; Sun Q; Wu J; Liu S
    Front Pharmacol; 2023; 14():1159829. PubMed ID: 37601051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of exosomal PD-L1 in tumor progression and immunotherapy.
    Xie F; Xu M; Lu J; Mao L; Wang S
    Mol Cancer; 2019 Oct; 18(1):146. PubMed ID: 31647023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of exosomal PD-L1 in tumor immunotherapy.
    Wang J; Zeng H; Zhang H; Han Y
    Transl Oncol; 2021 May; 14(5):101047. PubMed ID: 33647542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shedding Light on the Role of Exosomal PD-L1 (ExoPD-L1) in Cancer Progression: an Update.
    Sun D; Altalbawy FMA; Yumashev A; Hjazi A; Menon SV; Kaur M; Deorari M; Abdulwahid AS; Shakir MN; Gabal BC
    Cell Biochem Biophys; 2024 Jun; ():. PubMed ID: 38907940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exosomal PD-L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies.
    Zhou K; Guo S; Li F; Sun Q; Liang G
    Front Cell Dev Biol; 2020; 8():569219. PubMed ID: 33178688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients.
    Li C; Li C; Zhi C; Liang W; Wang X; Chen X; Lv T; Shen Q; Song Y; Lin D; Liu H
    J Transl Med; 2019 Oct; 17(1):355. PubMed ID: 31665020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The link between intracellular calcium signaling and exosomal PD-L1 in cancer progression and immunotherapy.
    Alam MR; Rahman MM; Li Z
    Genes Dis; 2024 Jan; 11(1):321-334. PubMed ID: 37588227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of Exosomal PD-L1 RNA in Saliva of Patients With Periodontitis.
    Yu J; Lin Y; Xiong X; Li K; Yao Z; Dong H; Jiang Z; Yu D; Yeung SJ; Zhang H
    Front Genet; 2019; 10():202. PubMed ID: 30923536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exosomal and Soluble Programed Death-Ligand 1 (PD-L1) Predicts Responses to Pembrolizumab in Patients with Extranodal NK/T-Cell Lymphoma.
    Kim SJ; Ryu KJ; Park B; Yoon SE; Cho J; Park Y; Kim WS
    Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.
    Ott PA; Bang YJ; Piha-Paul SA; Razak ARA; Bennouna J; Soria JC; Rugo HS; Cohen RB; O'Neil BH; Mehnert JM; Lopez J; Doi T; van Brummelen EMJ; Cristescu R; Yang P; Emancipator K; Stein K; Ayers M; Joe AK; Lunceford JK
    J Clin Oncol; 2019 Feb; 37(4):318-327. PubMed ID: 30557521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.